15. The Economics of Longevity

Investors are fueling the anti-aging boom, attracted by the massive potential for profit and global impact. In 2024, the clinical and off-label therapeutic segment commanded 59% of the market, reflecting strong demand for evidence-based interventions. Grand View Research details how financial stakes are driving innovation and accessibility in longevity science.